Profile data is unavailable for this security.
About the company
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.
- Revenue in CAD (TTM)0.00
- Net income in CAD-2.60m
- Incorporated2004
- Employees--
- LocationClaritas Pharmaceuticals Inc4040 Civic Center Drive, Suite 200SAN RAFAEL 94903United StatesUSA
- Phone+1 (416) 362-4441
- Fax+1 (403) 266-8647
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Zenith Capital Corp | 0.00 | -14.38m | 766.78k | -- | -- | -- | -- | -- | -0.0951 | -0.0951 | 0.00 | -0.1795 | 0.00 | -- | -- | -- | -200.28 | -- | -- | -- | -- | -- | -- | -- | -- | -5.18 | -- | -- | -- | -- | 19.24 | -- | -- | -- |
Psybio Therapeutics Corp | 0.00 | -3.83m | 839.95k | 4.00 | -- | -- | -- | -- | -0.0328 | -0.0328 | 0.00 | -0.018 | 0.00 | -- | -- | -- | -357.70 | -- | -- | -- | -- | -- | -- | -- | -- | -617.30 | -- | -- | -- | -- | 55.66 | -- | -- | -- |
Claritas Pharmaceuticals Inc | 0.00 | -2.60m | 949.70k | -- | -- | -- | -- | -- | -0.0845 | -0.2023 | 0.00 | 0.1257 | 0.00 | -- | -- | -- | -17.49 | -33.39 | -51.79 | -39.16 | -- | -- | -- | -- | -- | 6.86 | 0.1409 | -- | -- | -- | 119.85 | -- | -- | -- |
Waverley Pharma Inc | 144.82k | -2.25m | 1.35m | -- | -- | -- | -- | 9.32 | -0.0417 | -0.0417 | 0.0027 | -0.0323 | 0.0984 | 2.22 | 2.38 | -- | -153.02 | -32.30 | -- | -60.75 | -16.68 | 13.74 | -1,555.37 | -94.30 | 0.0995 | -9.94 | 8.80 | -- | -66.95 | 13.03 | -234.91 | -- | -- | -- |
Vaxil Bio Ltd | 0.00 | -110.00k | 1.37m | -- | -- | 1.74 | -- | -- | -0.0008 | -0.0008 | 0.00 | 0.0058 | 0.00 | -- | -- | -- | -10.99 | -65.45 | -13.02 | -116.22 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 56.51 | -- | -- | -- |